78/100BEdwards Lifesciences company profile
- CEO
- Bernard J. Zovighian
- Employees
- 16,000
- Headquarters
- One Edwards Way, Irvine, CA 92614, US
- Sector
- Healthcare
- Industry
- Medical - Devices
- IPO date
- 27 Mar 2000
- Stock exchange
- NYSE
- ISIN
- US28176E1082
Website:edwards.com
About the company
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Employees
Edwards Lifesciences had about 16,000 employees at the end of fiscal year 2025 (31 December 2025), by its annual report. That is 1.3% more than a year before.
Employees at each fiscal year end, as the company reports them in its annual report (10-K); revenue and net income per employee are the fiscal year's over that count.
Who owns Edwards Lifesciences
Institutions such as funds, banks and insurers held 90.8% of Edwards Lifesciences's shares on 30 June 2026, 1,377 of them reporting holdings to the SEC; the rest is held by individual investors and other shareholders.
Shares free to trade
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Common questions about Edwards Lifesciences
Source: Financial Modeling Prep